Gene Therapy INDs In China: Five Things To Consider
Executive Summary
China is overtaking the US as the largest cell development market, with over 2,300 registered clinical trials.
You may also be interested in...
A Wild CAR-T Race In China: The Hype, Reality And What Works
As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.